These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11317529)

  • 21. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
    Nishida M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
    Scarabelli L; Giovanardi F; Gervasi E; Prati G; Pezzuolo D; Scaltriti L
    Chemotherapy; 2013; 59(5):369-72. PubMed ID: 24821441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):571-2. PubMed ID: 12503818
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of capecitabine: a review.
    Mikhail SE; Sun JF; Marshall JL
    Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
    Chaigneau L; Royer B; Montange D; Nguyen T; Maurina T; Villanueva C; Demarchi M; Borg C; Fagnoni-Legat C; Kantelip JP; Pivot X
    Ann Oncol; 2008 Nov; 19(11):1980-1. PubMed ID: 18952760
    [No Abstract]   [Full Text] [Related]  

  • 29. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
    Patel PA
    Anticancer Drugs; 2011 Apr; 22(4):311-6. PubMed ID: 21301320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Capecitabine].
    Yamaguchi K; Shimamura T; Tada M
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
    Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
    Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
    Semiglazova TIu; Gershanovich ML
    Vopr Onkol; 2001; 47(3):298-302. PubMed ID: 11544827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
    Orel NF
    Ter Arkh; 2003; 75(10):65-70. PubMed ID: 14669610
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
    Vakhabova JV; Semenov NN; Dobrova NV; Lichinitser MR
    Bull Exp Biol Med; 2008 Feb; 145(2):249-51. PubMed ID: 19023981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Capecitabine in the treatment of colorectal cancer].
    Zeuli M; Pino MS; Cognetti F
    Tumori; 2001; 87(1 Suppl 1):S55-6. PubMed ID: 11300027
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
    Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
    Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.